Atsushi Enomoto, Ph.D., to Present his Research on Girdin
(Raleigh, N.C.) NagoyaUniversity (NU) and its North Carolina technology transfer office, Technology Partnership of Nagoya University (NU Tech), announced that Atsushi Enomoto, Ph.D., will make the opening technology presentation at the Diagnostics / Molecular Therapeutics Roundtable at the North Carolina Biotechnology Center on October 4, 2012. Dr. Enomoto will present his latest research findings on Girdin, a novel actin-binding protein that has the potential for use as a new therapeutic drug and diagnostic compound for cancer, diabetic retinopathy and other diseases. Girdin is a regulator for cell migration that is essential for postnatal angiogenesis, neurogenesis and cancer progression. Among other things, Dr. Enomoto’s research has shown that inhibition of Girdin decreases the malignancy and transformation of breast cancer in mice, and may also suppress retinal angiogenesis in mice. Dr. Enomoto is an Associate Professor in the Department of Pathology at the Nagoya University Graduate School of Medicine. His presentation on Girdin will be the first of five presentations to be made at the Diagnostics and Molecular Therapeutics Roundtable, an event being organized by NU Tech in cooperation with the University of North Carolina at Chapel Hill (UNC), North Carolina State University (NCSU) and Wake Forest University (WFU). (more…)
